Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.57 |
| ▸ | CA12 | O43570 | 4/20 | 0.50 |
| ▸ | CA9 | Q16790 | 4/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | NT5E | P21589 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 5/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2587850 | 1.00 | MAPT (0.57) | MAPTCA12CA9CA1CA2 | |
| SCHEMBL2590916 | 0.76 | MAOB (0.36) | MAPTKDM4ENT5EALDH1A1MAOB | |
| SCHEMBL28153425 | 0.72 | MAPT (0.73) | MAPTCA12CA9CA1CA2 | |
| SCHEMBL9670924 | 0.69 | MAPT (0.72) | MAPTCA12CA9CA1CA2 | |
| SCHEMBL9670927 | 0.69 | MAPT (0.72) | MAPTCA12CA9CA1CA2 | |
| SCHEMBL2587847 | 0.68 | MAPT (0.51) | MAPTCA12CA9CA1CA2 | |
| SCHEMBL8298413 | 0.68 | MAOB (0.69) | MAPTCA12CA9CA1CA2 | |
| SCHEMBL9668560 | 0.67 | CA12 (0.67) | MAPTCA12CA9CA1CA2 | |
| SCHEMBL16994328 | 0.67 | CCNE1 (0.46) | MAPTALDH1A1MEN1KMT2APOLB | |
| SCHEMBL28037533 | 0.66 | KDR (0.71) | MAPTCA12CA9CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2567225-A2 | LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS | Virginia Tech Intellectual Properties, Inc. (US) | 2013-03-13 | — | — | EP | claimed |
| WO-2011140215-A2 | LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2011-11-10 | — | — | WO | claimed |
| US-20110275558-A1 | LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2011-11-10 | — | — | US | claimed |
| EP-2567225-B1 | LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS | VIRGINIA TECH INTELLECTUAL PROPERTIES INC (US) | 2019-10-02 | — | — | EP | disclosed |
| US-20150241448-A1 | LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150241448-A1 | LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150241448-A1 | LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-9101573-B2 | Lanthionine synthetase component C-like proteins as molecular targets for preventing and treating diseases and disorders | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| EP-2567225-A2 | LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS | Virginia Tech Intellectual Properties, Inc. (US) | 2013-03-13 | — | — | EP | disclosed |
| WO-2011140215-A2 | LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| US-20110275558-A1 | LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275558-A1 | LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275558-A1 | LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275558-A1 | LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS | LANCL2, ACSL1, LANCL1 | MAPT 4166/4885CA12 1740/4885CA9 2107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.